Floatz logo

Capecitabine

Endocrine Gland Neoplasms

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Endocrine Gland Neoplasms cohort.

Asset / SponsorPhaseRating
Irinotecan
Xiaoxiang Chen
Phase 2BB
Denosumab
Amgen
Phase 2B
DEXAMETHASONE
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2B
Trabectedin
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2B
IMMUNOGLOBULIN G, ANTI-(HUMAN INSULIN-LIKE GROWTH FACTOR I RECEPTOR) (HUMAN MONOCLONAL HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL LIGHT CHAIN, DIMER
NantCell, Inc.
Phase 3CCC

View all 12 →

Same molecule, other indications

Capecitabine is also rated in:

Locally Advanced Rectal CancerDormant
BBB
Indicative ·
75 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →
rectal carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →